Promising Late-Stage Drugs Signal A New Treatment Era Delveinsight. The generalized myasthenia gravis treatment pipeline ...
Complement pathway proteins are involved in immunoglobulin A-containing immune complex (IgA-IC) formation and deposition in the kidneys. Elevated complement factor H-related protein 1 (CFHR1) may be a ...
Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing immune complexes (IgA-ICs) in the glomerular mesangium, leading to mesangial ...
First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...
According to the Department of Defense (DOD), the Terminal High Altitude Area Defense (THAAD) system (Figure 1) is a key element of U.S. ballistic missile defense (BMD). THAAD employs interceptor ...
Scientists pinpoint a skin alarm system pathway that links local damage to systemic immune responses
Skin, our largest organ, acts as a protective barrier against pathogens that try to invade our bodies while constantly monitoring for potential threats. In the skin's outermost layer, the epidermis, ...
SAP SE’s new bonus system ended up rewarding underperforming managers while holding lower-ranking workers to a higher standard for their payouts, prompting an outcry from employees and leaders alike ...
FREDERICK, Md., Feb. 18, 2026 /PRNewswire/ -- Do you know why passenger and freight planes are not using renewable biofuel? It's a simple reason - it costs too much. "Converting stems and leaves from ...
Comprehensive analysis outlines how vascular-immune crosstalk affects cancer, cardiovascular, and metabolic disorders, revealing novel therapeutic opportunities The intricate, lifelong conversation ...
A study published in Nature Medicine identified a link between the placebo effect and immune system function. In the experiment, individuals who generated positive expectations showed a stronger ...
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results